Premium
Clopidogrel therapy in patients undergoing coronary stenting: Value of a high‐loading‐dose regimen
Author(s) -
Pache Jürgen,
Kastrati Adnan,
Mehilli Julinda,
Gawaz Meinrad,
Neumann FranzJosef,
Seyfarth Melchior,
Hall Donald,
Braun Siegmund,
Dirschinger Josef,
Schömig Albert
Publication year - 2002
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.10092
Subject(s) - medicine , clopidogrel , ticlopidine , abciximab , regimen , loading dose , cardiology , myocardial infarction , angioplasty , coronary stent , concomitant , revascularization , percutaneous coronary intervention , surgery , stent , anesthesia , restenosis
The objective of this study was to assess the value of a clopidogrel regimen based on a high loading dose initiated before the stent placement procedure. A consecutive series of 864 patients treated with a high‐loading‐dose clopidogrel regimen (600 mg given 2–4 hr prior to intervention) was compared with 870 patients treated with conventional ticlopidine therapy. Abciximab was given periprocedurally in 62% of the patients. The composite endpoint of death, myocardial infarction, or urgent revascularization was reached by 39 (4.5%) clopidogrel patients and 59 (6.8%) ticlopidine patients. Clopidogrel therapy was associated with a 35% reduction of the risk for early adverse events (odds ratio 0.65; 95% confidence interval, 0.43–0.98). Thus, a high‐loading‐dose clopidogrel regimen in patients undergoing coronary artery stenting was safe and led to a more favorable clinical outcome than conventional therapy with ticlopidine regardless of concomitant treatment with abciximab. Cathet Cardiovasc Intervent 2002;55:436–441. © 2002 Wiley‐Liss, Inc.